Features | VJHemOnc

Omidubicel receives FDA approval for patients with hematological malignancies requiring stem cell transplantation

On April 17, 2023, the U.S. Food and Drug Administration (FDA) approved omidubicel, an allogeneic cord blood-derived cell therapy, for…

Chemotherapy: the backbone of lymphoma treatment

VJHemOnc is excited to present the latest developments in the role of chemotherapy across lymphomas

The role of MRD in multiple myeloma

VJHemOnc is pleased to bring you a feature exploring the emerging applications of MRD in multiple myeloma.

Novel agents in MDS

VJHemOnc is pleased to bring you a feature exploring the latest advances and developments in novel agents for MDS, with…

MRD as a clinical and regulatory endpoint for AML

VJHemOnc is pleased to bring you a feature exploring the latest thinking on the application of MRD in AML trials…

Pirtobrutinib receives accelerated FDA approval for the treatment of R/R mantle cell lymphoma

The Food and Drug Administration (FDA) granted accelerated approval to pirtobrutinib for the treatment of relapsed/refractory (R/R) mantle cell lymphoma…

Zanubrutinib receives FDA approval for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma

Zanubrutinib was approved by the Food and Drug Administration (FDA) on the 19th of January 2023, for the treatment of…

ASH late-breaking abstract rundown

VJHemOnc is thrilled to bring you the latest updates from the 64th American Society of Hematology (ASH) Annual Meeting and…